21 SF3B1 MUTATIONS INDUCE ABERRANT SPLICING LEADING TO A BLOCK IN ERYTHROID DIFFERENTIATION AND COMPETITIVE ADVANTAGE

20 SOMATIC MUTATIONAL MODEL TO PREDICT RESPONSE TO HYPOMETHYLATING AGENTS IN MYELODYSPLASTIC SYNDROMES A. Nazha1, T. Radivoyevitch2, S. Thota2, H. Makishima2, B. Patel2, D. Seastone1, H. Carraway1, J. Carew2, B. Przychodzen2, M. Kalaycio1, M. Sekeres1, J. Maciejewski2 1Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA; 2Translational Hematology and Oncology Research, Cleveland Clinic Taussig Cancer Institute, Cleveland, USA